2017

Small country, big thinkers: Why it’s only natural for the Netherlands to take on a pioneering role in snakebite advocacy

Staff Spotlight: Molly Lepeska

European Commission Appoints Health Action International to HTA Network Stakeholder Pool

2016

Health Action International Launches Study to Examine Access to Sexual and Reproductive Health Commodities in Kenya, Uganda and Zambia

Clinical Trial Data Transparency on Trial – EMA Under Pressure From Pharma Lawsuit

Next Gen Advocates Excel at HAI/HP4L Summer School on Access to Medicines

Top Experts to Discuss Global Initiatives to Reduce Snakebite Death & Disability at WHA69 Side Event

ACCISS Infographics

Farewell to Access to Medicines Pioneer, Andrew Herxheimer

Insulin Still Unattainable for Many Living with Diabetes Worldwide: ACCISS Study Review in The Lancet D&E

2015

HAI/WHO Pharmaceutical Promotion Manual Still Key to Combating Promotion around the World

HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe

HAI urges MEPs to support key amendments to TTIP resolution

The EU-US Trade Deal Could Leave Europeans Sick

HAI Launches Innovative Global Study to Improve Access to Insulin

2014

More work needed on new EMA conflicts of interest policy

EMA policy on clinical data publication a step ahead, but falls short of true potential

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA

School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis

Setting precedents: EMA must get clinical trial data policy right to truly act in public interest

HAI Europe calls on EMA's Management Board to stand for data transparency

Tamiflu review shows desperate need for full clinical trials data transparency

A new (and improved) model to regulate pharmaceutical promotion

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

Bayer CEO's callous comments highlight failure of current biomedical innovation model

2013

When politicians go to the movies

2011

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

European drug regulator challenged over revolving door case involving former Director

Corporate funding linked to EU patient & consumer groups policy